Clinical Trial Update: Venetoclax and Ibrutinib in Treating in Participants With Chronic Lymphocytic Leukemia and Ibrutinib Resistance Mutations [Phase 2]

View source ↗

Summary

This is a Phase 2 clinical trial update assessing the combination of venetoclax and ibrutinib in participants with chronic lymphocytic leukemia who have ibrutin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• Ibrutinib (ibrutinib)
• Venetoclax (venetoclax)

Snippet

Sponsor: Ohio State University Comprehensive Cancer Center | Conditions: Chronic Lymphocytic Leukemia, Ibrutinib Resistance | Phase 2 | Status: ACTIVE_NOT_RECRUITING